Next Article in Journal
Overexpression of a Multiprotein Bridging Factor 1 Gene DgMBF1 Improves the Salinity Tolerance of Chrysanthemum
Next Article in Special Issue
Circadian (De)regulation in Head and Neck Squamous Cell Carcinoma
Previous Article in Journal
Mitochondria in Neuroprotection by Phytochemicals: Bioactive Polyphenols Modulate Mitochondrial Apoptosis System, Function and Structure
Previous Article in Special Issue
A Robust Model for Circadian Redox Oscillations
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 20
Issue 10
10.3390/ijms20102452
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Melatonin MT1 and MT2 Receptors Exhibit Distinct Effects in the Modulation of Body Temperature across the Light/Dark Cycle

by
Martha López-Canul
1,†,
Seung Hyun Min
1,†,
Luca Posa
1,2,
Danilo De Gregorio
1,
Annalida Bedini
3,
Gilberto Spadoni
3,
Gabriella Gobbi
1,* and
Stefano Comai
1,4
1
Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University Health Center (MUHC), McGill University, Montreal, QC H3A1A1, Canada
2
Alan Edwards Centre for Research on Pain, McGill University, Montreal, QC H3A 0G1, Canada
3
Department of Biomolecular Sciences, University Carlo Bo, 61029 Urbino, Italy
4
Neuropsychopharmacology Unit, San Raffaele Scientific Institute and Vita-Salute University, 20132 Milan, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(10), 2452; https://doi.org/10.3390/ijms20102452
Submission received: 15 April 2019 / Revised: 6 May 2019 / Accepted: 10 May 2019 / Published: 17 May 2019
(This article belongs to the Special Issue Circadian Rhythms: Molecular and Physiological Mechanisms)
Browse Figures
Versions Notes

Abstract

:
Melatonin (MLT) is a neurohormone that regulates many physiological functions including sleep, pain, thermoregulation, and circadian rhythms. MLT acts mainly through two G-protein-coupled receptors named MT1 and MT2, but also through an MLT type-3 receptor (MT3). However, the role of MLT receptor subtypes in thermoregulation is still unknown. We have thus investigated the effects of selective and non-selective MLT receptor agonists/antagonists on body temperature (Tb) in rats across the 12/12-h light–dark cycle. Rectal temperature was measured every 15 min from 4:00 a.m. to 9:30 a.m. and from 4:00 p.m. to 9:30 p.m., following subcutaneous injection of each compound at either 5:00 a.m. or 5:00 p.m. MLT (40 mg/kg) had no effect when injected at 5 a.m., whereas it decreased Tb during the light phase only when injected at 5:00 p.m. This effect was blocked by the selective MT2 receptor antagonist 4P-PDOT and the non-selective MT1/MT2 receptor antagonist, luzindole, but not by the α1/MT3 receptors antagonist prazosin. However, unlike MLT, neither the selective MT1 receptor partial agonist UCM871 (14 mg/kg) nor the selective MT2 partial agonist UCM924 (40 mg/kg) altered Tb during the light phase. In contrast, UCM871 injected at 5:00 p.m. increased Tb at the beginning of the dark phase, whereas UCM924 injected at 5:00 a.m. decreased Tb at the end of the dark phase. These effects were blocked by luzindole and 4P-PDOT, respectively. The MT3 receptor agonist GR135531 (10 mg/kg) did not affect Tb. These data suggest that the simultaneous activation of both MT1 and MT2 receptors is necessary to regulate Tb during the light phase, whereas in a complex but yet unknown manner, they regulate Tb differently during the dark phase. Overall, MT1 and MT2 receptors display complementary but also distinct roles in modulating circadian fluctuations of Tb.

1. Introduction

The maintenance of body temperature (Tb) in mammalians is critical for survival and internal homeostasis. The main brain structure involved in controlling Tb is the hypothalamus, which receives inputs from the thermoreceptors located in both the brain and the periphery. Depending on these inputs, homeostatic changes are subsequently induced, causing sweating or shivering [1]. In particular, the preoptic area (POA) and dorsomedial hypothalamus (DMH) are critical hypothalamic areas for thermoregulation. In these areas, based on the firing rate responses to changes in local brain temperature, electrophysiological recordings have shown three different neuronal populations: warm-sensitive neurons (~30%), cold-sensitive neurons (~6%), and insensitive neurons (~60%), [2,3]. Activation of the thermally-responsive GABAergic and glutamatergic neurons in the ventral part of the lateral preoptic nucleus (vLPO) and the dorsal part of the dorsomedial hypothalamus (DMD), respectively, decreases temperature, physical activity, and metabolic rate. On the contrary, GABAergic neurons in the DMD promote the increase of Tb, energy expenditure, and physical activity [4].
Recently, it has also been found that Tb can be internally regulated in a circadian manner by endogenous signals from other parts of the hypothalamus [4,5], specifically in the suprachiasmatic nucleus (SCN) [1,6,7]. The SCN regulates the circadian rhythmicity of several physiological responses [1], including the oscillatory decrease of the thermoregulatory threshold of heat production during day time and heat loss during night time in diurnal species [1,8,9]. However, the mechanisms underlying this circadian modulation of Tb remain unclear. Interestingly, the hypothalamus, including the SCN, DMH, and POA, are rich in melatonin (MLT) MT1 and MT2 receptors [7,10,11,12,13], and the activation of these MLT receptors modulates numerous physiological effects including the control of Tb [14].
MLT is produced in the pineal gland, mostly during the dark phase in both diurnal and nocturnal species [12,15]. The circadian production and release of MLT are controlled by the SCN [16]. Most of the physiological effects of MLT result from the activation of two high-affinity G-protein coupled receptors (GPCRs), MT1 (pKi = 10.09) and MT2 (pKi = 9.42), both of which are widely expressed in the mammalian brain [7,10,17]. The specific localization of the two MLT receptor subtypes in different regions of the brain and/or neuronal populations [11,18,19,20] partially explains the selective and differential functional activity of the two MLT receptor subtypes, such as in sleep [18,21,22,23], anxiety [24], pain [25,26], circadian rhythms [27], and depression [28]. In addition to these high-affinity MLT receptors, another low-affinity MLT binding site, termed MT3 (pKi = 6.0), has been reported [29,30]. Given its both hydrophilic and lipophilic nature, MLT can easily pass through the cell membrane and bind nuclear receptors, including retinoic acid receptor-related orphan receptors (RORs) [31].
It is known that MLT decreases Tb during the night in diurnal species [1]. Clinical studies have shown that exogenous administration of MLT suppresses the physiological increase in Tb observed during daytime [32,33] and has hypothermic properties at the dose of 5 mg/kg [34,35,36,37,38]. Similar results have been demonstrated in preclinical studies in diurnal animals in which administration of MLT acted as a hypothermic agent in the active/light phase in fat sand rats and Marshall broiler chickens [39,40]. However, the neurobiological mechanism through which MLT exerts this hypothermic effect, as well as the selective contribution of the three MLT receptor subtypes, are yet to be investigated.
Therefore, we investigated modifications in Tb produced by selectively activating the three MLT receptor subtypes across the light–dark cycle in rats. To achieve this aim, we tested the effects of the selective MT2 receptor partial agonist N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino] ethyl}acetamide (UCM924) (pKiMT1 = 6.76; pKiMT2 = 9.27) [41], the selective MT1 receptor partial agonist N-(2-{Methyl-[3-(4-phenylbutoxy)phenyl]amino}ethyl) acetamide (UCM871) (pKiMT1 = 8.93; pKiMT2 = 7.04) [42], and the MT3 receptor agonist 5-Methoxycarbonylamino-N-acetyltryptamine (GR135531) (pKiMT3 = 29.5) on Tb. The effects of UCM924, UCM871, and GR135531 were compared to those of MLT. In addition, selective and non-selective MLT receptor antagonists were also tested together with MLT and the other MLT receptor agonists/partial agonists to further dissect the MLT receptor subtypes involved in their thermoregulatory effects.

2. Results

In physiological conditions, as already known [1,9], there are changes in Tb between the light and the dark phase; in particular, Tb oscillations mostly occur during the phase shift (Figure 1). During the shift from the dark to the light phase, the Tb drops from an average of 38.45 to 37.5 °C after the light turns on (Figure 1A). The opposite occurs during the shift from the light to the dark phase when the light is turned off (Figure 1B).

2.1. Effects of MLT Injected at the End of the Dark and of the Light Phases on Tb

As indicated in Figure 2A, the injection of MLT (40 mg/kg) at the end of the dark phase (5:00 a.m.) did not affect Tb during the end of the dark phase, the dark–light transition or the beginning of the light phase (two-way repeated measures ANOVA; interaction: F17,323 = 0.85, p = 0.635; treatment: F1,323 = 0.867, p = 0.363; time of the day: F17,323 = 31.835, p < 0.001).
In contrast, when MLT (40 mg/kg) was injected at the end of the light phase (5:00 p.m.), it induced a significant decrease (p < 0.05) in Tb from 5:45 p.m. to 6:45 p.m. that was close to the transition from the light to the dark phase (Figure 2B; interaction: F17,408 = 1.908, p = 0.016; treatment: F1,408 = 1.996, p = 0.171; time of the day: F17,408 = 10.658, p < 0.001). Importantly, we observed no further effects of MLT on Tb after the light–dark transition or during the beginning of the dark phase. The selective MT2 receptor antagonist 4P-PDOT at a dose not affecting Tb (Figure 2D; interaction: F17,340 = 0.62, p = 0.876; treatment: F1,340 = 2.07, p = 0.166; time of the day: F17,340 = 4.86, p < 0.001) blocked the effects of MLT (Figure 2C; interaction: F17,391 = 1.448, p = 0.111; treatment: F1,391 = 0.22, p = 0.643; time of the day: F17,391 = 11.486, p < 0.001). Similarly, the pre-treatment with the selective MT1/MT2 receptor antagonist luzindole at the dose not affecting Tb (Figure 2F; interaction: F17,408 = 1.144, p = 0.309; treatment: F1,408 = 0.012, p = 0.912; time of the day: F17,408 = 9.289, p < 0.001) also blocked the effects of MLT (Figure 2E; interaction: F17,289 = 0.989, p = 0.47; treatment: F1,289 = 0.11, p = 0.745; time of the day: F17,289 = 3.745, p < 0.001).

2.2. Effects of the Selective MT2 Partial Agonist UCM924 Injected at the End of the Dark and of the Light Phases on Tb

As indicated in Figure 3A, the injection of UCM924 (40 mg/kg) at the end of the dark phase (5:00 a.m.) induced a significant decrease (p < 0.05) in Tb immediately before the dark–light transition (from 6:45 a.m. to 7:30 a.m.), and did not affect Tb during the dark–light transition and at the beginning of the light phase (two-way repeated measures ANOVA; interaction: F17,289 = 0.2.406, p = 0.002; treatment: F1,289 = 2.286, p = 0.149; time of the day: F17,289 = 30.597, p < 0.001).
In contrast, when UCM924 (40 mg/kg) was injected during the light phase (5:00 p.m.), it did not affect Tb during the end of the light phase, the dark–light transition or the beginning of the dark phase (Figure 3B; two-way repeated measures ANOVA; interaction: F17,425 = 0.785, p = 0.711; treatment: F1,425 = 0.311, p = 0.582; time of the day: F17,425 = 9.618, p < 0.001).
The effects of UCM924 on Tb when injected during the dark phase were mediated by MT2 receptors since the pre-treatment with the selective MT2 receptor antagonist 4P-PDOT at a dose not affecting Tb (Figure 3D; interaction: F17,272 = 0.875, p = 0.605; treatment: F1,272 = 1.223, p = 0.285; time of the day: F17,272 = 22.848, p < 0.001) blocked the effects of UCM924 (Figure 3C; interaction: F17,272 = 1.922, p = 0.016; treatment: F1,272 = 0.0.35, p = 0.821; time of the day: F17,272 = 30.468, p < 0.001).

2.3. Effects of the Selective MT1 Partial Agonist UCM871 Injected at the End of the Dark and of the Light Phases on Tb

As indicated in Figure 4A, the injection of UCM871 (14 mg/kg) at the end of the dark phase (5:00 a.m.) did not affect Tb during the end of dark phase, the dark–light transition or the beginning of light phase (two-way repeated measures ANOVA; interaction: F17,340 = 0.842, p = 0.644; treatment: F1,340 = 0.538, p = 0.472; time of the day: F17,340 = 44.622, p < 0.001).
In contrast, when UCM871 (14 mg/kg) was injected during the light phase (5:00 p.m.), it induced a significant increase (p < 0.05) in Tb from 8:15 p.m. to 8:45 p.m. (dark phase) (Figure 4B; interaction: F17,340 = 1.634, p = 0.05; treatment: F1,340 = 2.045, p = 0.168; time of the day: F17,340 = 10.42, p < 0.001). The effects of UCM871 on Tb when injected during the light phase were blocked by the pre-treatment with the MT1/MT2 receptor antagonist luzindole (Figure 4C; interaction: F17,340 = 0.67, p = 0.83; treatment: F1,340 = 1.22, p = 0.28; time of the day: F17,340 = 4.88, p < 0.001) at a dose not affecting Tb (see Figure 2F; interaction: F17,408 = 1.144, p = 0.309; treatment: F1,408 = 0.012, p = 0.912; time of the day: F17,408 = 9.289, p < 0.001).

2.4. Effects of the Selective MT3 Agonist GR135531 and Prazosin Injected at the End of the Light Phase on Tb

As indicated in Figure 5A, the injection of GR135531 (10 mg/kg) at the end of the light phase (5:00 p.m.) did not affect Tb during the end of the light phase, the dark–light transition or the beginning of dark phase (two-way repeated measures ANOVA; interaction: F17,306 = 0.94, p = 0.527; treatment: F1,306 = 0.342, p = 0.566; time of the day: F17,306 = 7.817, p < 0.001). The effects of MLT on Tb, when injected during the light phase, were not mediated by MT3 receptors, since the pre-treatment with the non-selective α1/MT3 antagonist prazosin at a dose not affecting Tb (Figure 5C, interaction: F17,357 = 1.01, p = 0.446; treatment: F1,357 = 0.022, p = 0.882; time of the day: F17,357 = 7.588, p < 0.001) did not block the effects of MLT (Figure 5B; interaction: F17,340 = 1.65, p = 0.050; treatment: F1,340 = 3.064, p = 0.095; time of the day: F17,340 = 10.086, p < 0.001). Interestingly, the treatment with prazosin plus MLT induced a further decrease of Tb even during the dark phase at 8:00 p.m. (Figure 5B) that was not observed with MLT (Figure 2B) or prazosin (Figure 5C) alone.

3. Discussion

In this study, we investigated the effects of MLT and its three receptors on Tb during the light and the dark phase for the first time. To achieve this aim, we used a pharmacological approach employing MLT, the selective MT1 receptor partial agonist UCM871, the selective MT2 receptor partial agonist UCM924, the MT3 receptor agonist GR135531, and selective/non-selective MLT receptor antagonists, including the MT2 selective antagonist 4P-PDOT, the MT1/MT2 non-selective antagonist luzindole, and the MT3/α1 antagonist prazosin. The exogenous administration of MLT during the light phase decreased Tb immediately after the administration and before the light–dark phase shift, an effect blocked by both 4P-PDOT and luzindole. Interestingly, unlike MLT, neither UCM924 nor UCM871 produced a change in Tb during the light phase. In contrast, the selective MT2 partial agonist UCM924 administered at the end of the dark phase decreased Tb during the dark phase, just prior to the dark–light switch, whereas the selective MT1 partial agonist UCM871 injected at the end of the light phase increased Tb during the following dark phase. On the other hand, MT3 receptors did not seem to be involved in the regulation of Tb, since the MT3 receptor agonist GR135531 and the MT3/α1 antagonist prazosin alone had not produced any effect on Tb.
The rat circadian body temperature displays a cosine wave [39], showing a temperature that oscillates around the 35.6–36 °C during the light phase and around 37.8–38 °C during the dark phase [43]. The daily change in Tb shows a characteristic deviation at two different times, consistent with the switch between day (light phase) and night (dark phase) hours [44]. The present study replicates the same physiological Tb deviation that was previously reported in nocturnal rodents [43,44], with a daily Tb peak during the night, which is concomitant with the increase in the activity of the animals [45].
In nocturnal rodents, Tb peaks during night time when MLT levels are high, and decreases during the light phase when MLT levels are low. In contrast, in diurnal species, Tb regulation follows the reverse direction in relation to MLT levels, showing a Tb peak during the light phase [45] when circulating levels of MLT are very low (~10 pg/mL) [12,15,46]. However, the mechanism by which MLT regulates Tb has not been established.
The neuronal circuit controlling the regulation of Tb involves several structures including the SCN, SON, mPOA, and DMH [4,5]. Notably, the hypothalamus is an area rich in MLT receptors [11], and their expression may vary according to the phase and the time of the day [47,48,49,50,51].
Previous reports have shown that exogenous MLT administration during the light phase induced a decrease in Tb in both humans and rodents [32,35,36,37,39,52], although the active doses in humans are lower than those in rodents due to a significantly faster metabolism and very short half-life of MLT in the latter [53]. Our findings confirm that exogenous MLT influences Tb, and its effects are strictly dependent on the time of day: MLT reduces Tb only towards the end of the light phase and if administered during the light phase. In regard to its possible mechanism of action during the light phase, we found that both the selective MT2 antagonist 4P-PDOT and the non-selective MT1/MT2 antagonist luzindole blocked the Tb reduction due to MLT, yet neither the selective MT1 partial agonist UCM871 nor the selective MT2 partial agonist UCM924 recapitulated the effects of MLT on Tb. These findings suggest that during the light phase, MLT needs to simultaneously activate both MT1 and MT2 receptors to modulate Tb. Indeed, the selective activation/inhibition of only MT1 or MT2 receptors did not affect Tb during the day. In contrast, UCM871 and UCM924 produced changes in Tb at different times of the dark phase and of opposite magnitude: UCM871 enhanced Tb just after the light–dark transition, whereas UCM924 decreased Tb just before the dark–light transition. Importantly, unlike UCM871 and UCM924, MLT did not induce any change in Tb during the dark phase. We previously observed a similar time-of-day-dependent effect of MLT on sleep [23]. However, it is interesting that when α1 receptors/MT3 receptors were blocked by prazosin, MLT decreased Tb also during the dark phase. These complex findings observed during the dark phase are likely dependent on the fact that during the dark phase there is a significant increase in the endogenous levels of MLT, and thus the expression of the two MLT receptors [19], as well as the involvement of other receptors implicated in thermoregulation, such as α1 adrenoceptors [54], probably vary.
Interestingly, it is now well recognized that MLT receptors can form MT1/MT2 hetero-oligomers and also heteromers with other receptors, and from a functional point of view, their properties are different from those of the corresponding homomers [55,56]. Since MLT receptors as well as other receptors including α1-adrenoceptors are highly expressed in brain regions/nuclei involved in thermoregulation, we cannot exclude that some of the effects of MLT on Tb described here were mediated by these oligomers/heteromers. Future studies are needed to investigate the possible circadian variability in the formation and role of oligomers and/or heteromers of MLT receptors in hypothalamic nuclei regulating Tb. Similarly, the potential contribution of nuclear receptors, among which RORs that are also activated by MLT [31], is worth investigating.
The phase-dependent response of Tb to exogenous MLT may depend not only on the changes in the density of MLT receptors across the light–dark cycle, but also on the relative distribution and function of MT1 and MT2 receptors that control unique physiological responses in the brain, for example in sleep [21,22,23], anxiety [18,24], pain [25,26,57], and depression [28,58,59], and in the periphery, for example at the cardiovascular level [60,61].
In conclusion, we have investigated the role of MLT receptors in thermoregulation, and found that during the light phase Tb is affected only if both MT1 and MT2 receptors are simultaneously activated. Further, during the dark phase, a time-dependent effect was found in that the activation of MT1 and MT2 produces an increase and decrease of Tb respectively. No effects on Tb of the MLT MT3 receptor subtype were evidenced. However, MT1 and MT2 receptors control Tb in synergy with other receptors including α1 adrenoceptors. These data further support the recent findings showing that the MT1 and MT2 receptors modulate physio-pathological functions in different and sometimes opposing ways, and in a time-of-day dependent manner. In particular, MT1 or MT2 agonists may be further tested for hypothermia or hyperthermia, respectively.

4. Materials and Methods

4.1. Animals

Male Wistar rats (200–250 g, Charles River) were used for behavioral tests. All animals were housed at constant room temperature (20 °C) and humidity under a 12/12-h light–dark cycle (lights on at 7:30 a.m. and off at 7:30 p.m.) with food and water ad libitum. All experimental procedures were performed between 5:00 a.m. and 9:30 a.m. and between 5:00 p.m. to 9:30 p.m. The experimental protocol was approved by the Animal Ethics Committee (AUP#5253, McGill University, QC, Canada) and followed the ethical guidelines of the Canadian Institute of Health Research for animal care and scientific use.

4.2. Drugs and Pharmacological Treatments

The N-(2-{Methyl-[3-(4-phenylbutoxy)phenyl]amino}ethyl)acetamide (UCM871, 14 mg/kg) [42] and N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino] ethyl}acetamide (UCM924, 40 mg/kg) [41] were synthesized by the University of Urbino, Italy, and by BioQuadrant Inc. (Montreal, Canada), respectively. Melatonin (40 mg/kg), luzindole (10 mg/kg), and prazosin hydrochloride (1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochloride; 10 mg/kg) were purchased from Sigma (St. Louis, MO, USA), and 4P-PDOT (4-phenyl-2-propionamidotetralin; 10 mg/kg) and GR135531 (5-Methoxycarbonylamino-N-acetyltryptamine, 10 mg/kg) from Tocris Bioscience (Ellisville, MO, USA). All drugs were dissolved in a vehicle composed of 70% dimethyl sulfoxide (MP Biochemicals, Solon, OH, USA) and 30% saline. The doses of UCM924, MLT, 4P-PDOT, and luzindole [23,25,26], as well as UCM871 [62], were chosen based on our previous experiments examining the potential pharmacological activity of these compounds. The doses of GR135531 and prazosin were based on the literature [63,64]. Drugs were injected subcutaneously (s.c.; 0.5 mL) 15 min before the beginning of the experiment: 5:00 a.m. for dark–light or 5:00 p.m. for light–dark testing. The selective MLT MT2 receptor antagonist 4P-PDOT, the non-selective MLT MT1/MT2 receptor antagonist luzindole, and the MT3/α1 antagonist prazosin (pKi = 21.7) [65] were injected 15 min prior the agonist/partial agonist. Figure 6 describes the experimental protocol.

4.3. Assessment of Body Temperature

Body (rectal) temperature (Tb) in awake animals was measured by goosing the animal using a Traceable Snap-in Module with probe (Fisher Science Education, S90862). The probe was inserted to a depth of 2 cm for no more than 10 s, whereas the tested individual was kept in a cotton bag. Animals were handled every day for five days before the experiments with the aim of habituating the animal to the testing procedure and thus minimizing the associated stress.

4.4. Statistical Analysis

Data analysis was conducted using the SigmaPlot statistical software version 13 (Systat Software, Inc.). After controlling for the normal distribution of the data, a two-way ANOVA for repeated measures was used to analyze the data using treatments (between) and testing time (within) as factors. Post hoc analyses were performed using the Bonferroni test for multiple comparisons. The effect of vehicle was compared with that of the different agonists/partial agonists, the antagonists alone, or the agonist/partial agonist plus the antagonist. All data were expressed as mean ± SEM. p < 0.05 was considered significant. All figures were made using MATLAB software.
Temperature values were normalized as follow: [Temperature at time X – Average of Temperature (4:00 a.m./p.m. to 5:00 a.m./p.m.)]/[Average of Temperature (4:00 a.m./p.m. to 5:00 a.m./p.m.)]. “Time X” indicates any time after the injection.

Author Contributions

Conceptualization, G.G.; Data curation, M.L.-C., S.H.M., and S.C.; Formal analysis, M.L.-C. and S.C.; Investigation, M.L.-C., S.H.M., L.P., and D.D.G.; Project administration, G.G.; Resources, A.B. and G.S.; Supervision, G.G. and S.C.; Writing—original draft, M.L.-C. and S.H.M.; Writing—review & editing, G.G. and S.C.

Funding

This work was supported by grants from the Ministère de l’Économie, Science et Développement du Québec (MESI-PSR-SIIRI) and the Canadian Institutes of Health Research (CIHR, MOP-130285) to G.G. M.L.C. is supported by the CONACyT (272351) and the Faculty of Medicine, McGill University, Ferring postdoctoral fellowship. L.P. received a PhD fellowship from the the Louise and Alan Edwards Foundation. D.D.G. is supported by a post-doctoral fellowship from the Fonds de la Recherché du Quebec en Santé (FRQS). S.C. is supported in part by a 2017 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation.

Conflicts of Interest

Dr. Gabriella Gobbi is an inventor and assignee in patents regarding selective melatonin MT2 agonists. The other authors declare no conflicts of interest.

References

  1. Krauchi, K.; Deboer, T. The interrelationship between sleep regulation and thermoregulation. Front. Biosci 2010, 15, 604–625. [Google Scholar] [CrossRef]
  2. Boulant, J.A. Role of the preoptic-anterior hypothalamus in thermoregulation and fever. Clin. Infect. Dis. 2000, 31, S157–S161. [Google Scholar] [CrossRef] [PubMed]
  3. Boulant, J.A. Counterpoint: Heat-induced membrane depolarization of hypothalamic neurons: An unlikely mechanism of central thermosensitivity. Am. J. Physiol. Regul. Integr. Comp Physiol. 2006, 290, R1481–R1484. [Google Scholar] [PubMed]
  4. Zhao, Z.D.; Yang, W.Z.; Gao, C.; Fu, X.; Zhang, W.; Zhou, Q.; Chen, W.; Ni, X.; Lin, J.K.; Yang, J.; et al. A hypothalamic circuit that controls body temperature. Proc. Natl. Acad. Sci. USA 2017, 114, 2042–2047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Liedtke, W.B. Deconstructing mammalian thermoregulation. Proc. Natl. Acad. Sci. USA 2017, 114, 1765–1767. [Google Scholar] [CrossRef] [Green Version]
  6. Krauchi, K.; Cajochen, C.; Pache, M.; Flammer, J.; Wirz-Justice, A. Thermoregulatory effects of melatonin in relation to sleepiness. Chronobiol. Int. 2006, 23, 475–484. [Google Scholar] [CrossRef] [PubMed]
  7. Ng, K.Y.; Leong, M.K.; Liang, H.; Paxinos, G. Melatonin receptors: Distribution in mammalian brain and their respective putative functions. Brain Struct. Funct. 2017, 222, 2921–2939. [Google Scholar] [CrossRef]
  8. Benstaali, C.; Mailloux, A.; Bogdan, A.; Auzeby, A.; Touitou, Y. Circadian rhythms of body temperature and motor activity in rodents their relationships with the light-dark cycle. Life Sci. 2001, 68, 2645–2656. [Google Scholar] [CrossRef]
  9. Krauchi, K.; Wirz-Justice, A. Circadian rhythm of heat production, heart rate, and skin and core temperature under unmasking conditions in men. Am. J. Physiol. 1994, 267, R819–R829. [Google Scholar] [CrossRef] [PubMed]
  10. Dubocovich, M.L.; Markowska, M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005, 27, 101–110. [Google Scholar] [CrossRef]
  11. Lacoste, B.; Angeloni, D.; Dominguez-Lopez, S.; Calderoni, S.; Mauro, A.; Fraschini, F.; Descarries, L.; Gobbi, G. Anatomical and cellular localization of melatonin MT1 and MT2 receptors in the adult rat brain. J. Pineal. Res. 2015, 58, 397–417. [Google Scholar] [CrossRef] [PubMed]
  12. Pandi-Perumal, S.R.; Srinivasan, V.; Maestroni, G.J.; Cardinali, D.P.; Poeggeler, B.; Hardeland, R. Melatonin: Nature’s most versatile biological signal? FEBS J. 2006, 273, 2813–2838. [Google Scholar] [CrossRef] [PubMed]
  13. Wu, Y.H.; Zhou, J.N.; Balesar, R.; Unmehopa, U.; Bao, A.; Jockers, R.; Van Heerikhuize, J.; Swaab, D.F. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: Colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J. Comp. Neurol. 2006, 499, 897–910. [Google Scholar] [CrossRef] [PubMed]
  14. Claustrat, B.; Leston, J. Melatonin: Physiological effects in humans. Neurochirurgie 2015, 61, 77–84. [Google Scholar] [CrossRef] [PubMed]
  15. Arendt, J. Melatonin. Clin. Endocrinol. 1988, 29, 205–229. [Google Scholar] [CrossRef]
  16. Klein, D.C.; Moore, R.Y.; Reppert, S.M. Suprachiasmatic Nucleus: The Mind’s Clock; Oxford University Press: Oxford, UK, 1991. [Google Scholar]
  17. Hardeland, R.; Poeggeler, B. Melatonin and synthetic melatonergic agonists: Actions and metabolism in the central nervous system. Cent. Nerv. Syst. Agents Med. Chem. 2012, 12, 189–216. [Google Scholar] [CrossRef] [PubMed]
  18. Comai, S.; Gobbi, G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: A novel target in psychopharmacology. J. Psychiatry Neurosci. 2014, 39, 6–21. [Google Scholar] [CrossRef] [PubMed]
  19. Gobbi, G.; Comai, S. Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep. Front. Endocrinol (Lausanne) 2019, 10, 87. [Google Scholar] [CrossRef]
  20. Gobbi, G.; Comai, S. Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep. J. Pineal Res. 2019, 66, e12544. [Google Scholar] [CrossRef]
  21. Comai, S.; Ochoa-Sanchez, R.; Gobbi, G. Sleep-wake characterization of double MT(1)/MT(2) receptor knockout mice and comparison with MT(1) and MT(2) receptor knockout mice. Behav. Brain Res. 2013, 243, 231–238. [Google Scholar] [CrossRef]
  22. Ochoa-Sanchez, R.; Comai, S.; Lacoste, B.; Bambico, F.R.; Dominguez-Lopez, S.; Spadoni, G.; Rivara, S.; Bedini, A.; Angeloni, D.; Fraschini, F.; et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J. Neurosci. 2011, 31, 18439–18452. [Google Scholar] [CrossRef]
  23. Ochoa-Sanchez, R.; Comai, S.; Spadoni, G.; Bedini, A.; Tarzia, G.; Gobbi, G. Melatonin, selective and non-selective MT1/MT2 receptors agonists: Differential effects on the 24-h vigilance states. Neurosci. Lett. 2014, 561, 156–161. [Google Scholar] [CrossRef]
  24. Ochoa-Sanchez, R.; Rainer, Q.; Comai, S.; Spadoni, G.; Bedini, A.; Rivara, S.; Fraschini, F.; Mor, M.; Tarzia, G.; Gobbi, G. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: Comparison with melatonin and diazepam. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39, 318–325. [Google Scholar] [CrossRef]
  25. Lopez-Canul, M.; Comai, S.; Dominguez-Lopez, S.; Granados-Soto, V.; Gobbi, G. Antinociceptive properties of selective MT(2) melatonin receptor partial agonists. Eur. J. Pharmacol 2015, 764, 424–432. [Google Scholar] [CrossRef] [PubMed]
  26. Lopez-Canul, M.; Palazzo, E.; Dominguez-Lopez, S.; Luongo, L.; Lacoste, B.; Comai, S.; Angeloni, D.; Fraschini, F.; Boccella, S.; Spadoni, G.; et al. Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways. Pain 2015, 156, 305–317. [Google Scholar] [CrossRef]
  27. Pevet, P. Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus. Expert Opin. Ther. Targets 2016, 20, 1209–1218. [Google Scholar] [CrossRef] [PubMed]
  28. Comai, S.; Ochoa-Sanchez, R.; Dominguez-Lopez, S.; Bambico, F.R.; Gobbi, G. Melancholic-Like behaviors and circadian neurobiological abnormalities in melatonin MT1 receptor knockout mice. Int. J. Neuropsychopharmacol. 2015, 18, pyu075. [Google Scholar] [CrossRef]
  29. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J.M.; Lefoulon, F.; Fauchere, J.L.; Delagrange, P.; Canet, E.; Boutin, J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol Chem 2000, 275, 31311–31317. [Google Scholar] [CrossRef]
  30. Slominski, R.M.; Reiter, R.J.; Schlabritz-Loutsevitch, N.; Ostrom, R.S.; Slominski, A.T. Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol. Cell Endocrinol. 2012, 351, 152–166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Hardeland, R. Melatonin: Signaling mechanisms of a pleiotropic agent. Biofactors 2009, 35, 183–192. [Google Scholar] [CrossRef]
  32. Cagnacci, A.; Elliott, J.A.; Yen, S.S. Melatonin: A major regulator of the circadian rhythm of core temperature in humans. J. Clin. Endocrinol Metab 1992, 75, 447–452. [Google Scholar]
  33. Hughes, R.J.; Badia, P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 1997, 20, 124–131. [Google Scholar] [CrossRef]
  34. Arendt, J.; Skene, D.J. Melatonin as a chronobiotic. Sleep Med. Rev. 2005, 9, 25–39. [Google Scholar] [CrossRef]
  35. Cagnacci, A. Melatonin in relation to physiology in adult humans. J. Pineal Res. 1996, 21, 200–213. [Google Scholar] [CrossRef]
  36. Cagnacci, A.; Soldani, R.; Romagnolo, C.; Yen, S.S. Melatonin-induced decrease of body temperature in women: A threshold event. Neuroendocrinology 1994, 60, 549–552. [Google Scholar] [CrossRef]
  37. Gilbert, S.S.; van den Heuvel, C.J.; Dawson, D. Daytime melatonin and temazepam in young adult humans: Equivalent effects on sleep latency and body temperatures. J. Physiol. 1999, 514, 905–914. [Google Scholar] [CrossRef]
  38. Marrin, K.; Drust, B.; Gregson, W.; Atkinson, G. A meta-analytic approach to quantify the dose-response relationship between melatonin and core temperature. Eur. J. Appl. Physiol. 2013, 113, 2323–2329. [Google Scholar] [CrossRef]
  39. Schwimmer, H.; Mursu, N.; Haim, A. Effects of light and melatonin treatment on body temperature and melatonin secretion daily rhythms in a diurnal rodent, the fat sand rat. Chronobiol. Int. 2010, 27, 1401–1419. [Google Scholar] [CrossRef]
  40. Sinkalu, V.O.; Ayo, J.O.; Adelaiye, A.B.; Hambolu, J.O. Ameliorative effects of melatonin administration and photoperiods on diurnal fluctuations in cloacal temperature of Marshall broiler chickens during the hot dry season. Int. J. Biometeorol. 2015, 59, 79–87. [Google Scholar] [CrossRef]
  41. Rivara, S.; Vacondio, F.; Fioni, A.; Silva, C.; Carmi, C.; Mor, M.; Lucini, V.; Pannacci, M.; Caronno, A.; Scaglione, F.; et al. N-(Anilinoethyl)amides: Design and synthesis of metabolically stable, selective melatonin receptor ligands. ChemMedChem 2009, 4, 1746–1755. [Google Scholar] [CrossRef]
  42. Rivara, S.; Pala, D.; Lodola, A.; Mor, M.; Lucini, V.; Dugnani, S.; Scaglione, F.; Bedini, A.; Lucarini, S.; Tarzia, G.; et al. MT1-selective melatonin receptor ligands: Synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. ChemMedChem 2012, 7, 1954–1964. [Google Scholar] [CrossRef]
  43. De Vries, J.; Strubbe, J.H.; Wildering, W.C.; Gorter, J.A.; Prins, A.J. Patterns of body temperature during feeding in rats under varying ambient temperatures. Physiol. Behav. 1993, 53, 229–235. [Google Scholar] [CrossRef]
  44. Briese, E. Normal body temperature of rats: The setpoint controversy. Neurosci. Biobehav. Rev. 1998, 22, 427–436. [Google Scholar] [CrossRef]
  45. McElhinny, T.L.; Smale, L.; Holekamp, K.E. Patterns of body temperature, activity, and reproductive behavior in a tropical murid rodent, Arvicanthis niloticus. Physiol. behav. 1997, 62, 91–96. [Google Scholar] [CrossRef]
  46. Karasek, M. Melatonin, human aging, and age-related diseases. Exp. Gerontol. 2004, 39, 1723–1729. [Google Scholar] [CrossRef]
  47. Pinato, L.; Ramos, D.; Hataka, A.; Rossignoli, P.S.; Granado, M.D.J.; Mazzetto, M.C.; Campos, L.M.G. Day/night expression of MT1 and MT2 receptors in hypothalamic nuclei of the primate Sapajus apella. J. Chem. Neuroanat. 2017, 81, 10–17. [Google Scholar] [CrossRef]
  48. Waly, N.E.; Hallworth, R. Circadian Pattern of Melatonin MT1 and MT2 Receptor Localization in the Rat Suprachiasmatic Nucleus. J. Circad. Rhythms 2015, 13, 1. [Google Scholar] [CrossRef]
  49. Masana, M.I.; Benloucif, S.; Dubocovich, M.L. Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J. Pineal Res. 2000, 28, 185–192. [Google Scholar] [CrossRef]
  50. Odo, M.; Koh, K.; Takada, T.; Yamashita, A.; Narita, M.; Kuzumaki, N.; Ikegami, D.; Sakai, H.; Iseki, M.; Inada, E.; et al. Changes in circadian rhythm for mRNA expression of melatonin 1A and 1B receptors in the hypothalamus under a neuropathic pain-like state. Synapse 2014, 68, 153–158. [Google Scholar] [CrossRef]
  51. Poirel, V.J.; Masson-Pevet, M.; Pevet, P.; Gauer, F. MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei. Brain Res. 2002, 946, 64–71. [Google Scholar] [CrossRef]
  52. Cagnacci, A.; Krauchi, K.; Wirz-Justice, A.; Volpe, A. Homeostatic versus circadian effects of melatonin on core body temperature in humans. J. Biol. Rhythms 1997, 12, 509–517. [Google Scholar] [CrossRef]
  53. Yeleswaram, K.; McLaughlin, L.G.; Knipe, J.O.; Schabdach, D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J. Pineal Res. 1997, 22, 45–51. [Google Scholar] [CrossRef]
  54. Alam, M.N.; Mallick, B.N. Role of lateral preoptic area alpha-1 and alpha-2 adrenoceptors in sleep-wakefulness and body temperature regulation. Brain Res. Bull. 1994, 35, 171–177. [Google Scholar] [CrossRef]
  55. Oishi, A.; Cecon, E.; Jockers, R. Melatonin Receptor Signaling: Impact of Receptor Oligomerization on Receptor Function. Int. Rev. Cell Mol. Biol. 2018, 338, 59–77. [Google Scholar] [PubMed]
  56. Kamal, M.; Gbahou, F.; Guillaume, J.L.; Daulat, A.M.; Benleulmi-Chaachoua, A.; Luka, M.; Chen, P.; Kalbasi Anaraki, D.; Baroncini, M.; Mannoury la Cour, C.; et al. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers. J. Biol. Chem. 2015, 290, 11537–11546. [Google Scholar] [CrossRef]
  57. Posa, L.; De Gregorio, D.; Gobbi, G.; Comai, S. Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain. Curr. Med. Chem. 2018, 25, 3866–3882. [Google Scholar] [CrossRef] [PubMed]
  58. Liu, J.; Clough, S.J.; Dubocovich, M.L. Role of the MT1 and MT2 melatonin receptors in mediating depressive- and anxiety-like behaviors in C3H/HeN mice. Genes Brain Behav. 2017, 16, 546–553. [Google Scholar] [CrossRef]
  59. Comai, S.; Lopez-Canul, M.; De Gregorio, D.; Posner, A.; Ettaoussi, M.; Guarnieri, F.; Gobbi, G. Melatonin MT1 receptor as a novel target in neuropsychopharmacology: MT1 ligands, pathophysiological and therapeutic implications and perspectives. Pharmacol. Res. 2019. [Google Scholar] [CrossRef]
  60. Doolen, S.; Krause, D.N.; Dubocovich, M.L.; Duckles, S.P. Melatonin mediates two distinct responses in vascular smooth muscle. Eur. J. Pharmacol. 1998, 345, 67–69. [Google Scholar] [CrossRef]
  61. Pandi-Perumal, S.R.; BaHammam, A.S.; Ojike, N.I.; Akinseye, O.A.; Kendzerska, T.; Buttoo, K.; Dhandapany, P.S.; Brown, G.M.; Cardinali, D.P. Melatonin and Human Cardiovascular Disease. J. Cardiovasc. Pharmacol. Ther. 2017, 22, 122–132. [Google Scholar] [CrossRef] [PubMed]
  62. Comai, S.; Posa, L.; Ochoa-Sanchez, R.; Spadoni, S.; Gobbi, G. Neuropsychopharmacological properties of novel melatonin MT1 receptor ligands. Eur. Neuropsychopharmacol. 2017, 27. [Google Scholar] [CrossRef]
  63. Pintor, J.; Pelaez, T.; Hoyle, C.H.; Peral, A. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: Further evidence for an MT3 receptor. Br. J. Pharmacol. 2003, 138, 831–836. [Google Scholar] [CrossRef] [PubMed]
  64. Zurowski, D.; Nowak, L.; Machowska, A.; Wordliczek, J.; Thor, P.J. Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. J. Physiol. Pharmacol. 2012, 63, 641–647. [Google Scholar]
  65. Molinari, E.J.; North, P.C.; Dubocovich, M.L. 2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine: A selective radioligand for the characterization of melatonin ML2 binding sites. Eur. J. Pharmacol. 1996, 301, 159–168. [Google Scholar] [CrossRef]
Ijms 20 02452 g001 550
Figure 1. Body temperature (Tb) changes during the light–dark cycle in rats exposed to a 12/12-h light–dark cycle. (A) Tb decreases during the transition from the dark phase to the light phase. (B) Tb increases during the transition from the light phase to the dark phase. Lights on at 7:30 a.m. and off at 7:30 p.m. Data represent mean value ± SEM. Veh: s.c. injection of vehicle.
Figure 1. Body temperature (Tb) changes during the light–dark cycle in rats exposed to a 12/12-h light–dark cycle. (A) Tb decreases during the transition from the dark phase to the light phase. (B) Tb increases during the transition from the light phase to the dark phase. Lights on at 7:30 a.m. and off at 7:30 p.m. Data represent mean value ± SEM. Veh: s.c. injection of vehicle.
Ijms 20 02452 g001
Ijms 20 02452 g002 550
Figure 2. Changes in Tb after MLT administration (40 mg/kg) during the light and the dark phase. (A) MLT does not produce changes in Tb when administrated at 5:00 a.m. (B) MLT administrated during the dark phase (5:00 p.m.) decreases the Tb immediately after the administration compared with vehicle treated rats. (C) 4P-PDOT (10 mg/kg) pre-treatment blocks the effect of MLT on Tb during the light phase. (D) 4P-PDOT (10 mg/kg) injected during the light phase does not affect Tb. (E) Pre-treatment with luzindole (10 mg/kg) blocks the effect of MLT on Tb during the light phase. (F) luzindole (10 mg/kg) injected during the light phase does not affect Tb. Data are expressed as mean ± SEM (graded shades). Lights on at 7:30 a.m. and off at 7:30 p.m. * p < 0.05 vs. vehicle; two-way ANOVA for repeated measures followed by Bonferroni post hoc test. Inj: s.c. injection of either vehicle, MLT, MLT + 4P-PDOT, 4P-PDOT, MLT + luzindole, or luzindole.
Figure 2. Changes in Tb after MLT administration (40 mg/kg) during the light and the dark phase. (A) MLT does not produce changes in Tb when administrated at 5:00 a.m. (B) MLT administrated during the dark phase (5:00 p.m.) decreases the Tb immediately after the administration compared with vehicle treated rats. (C) 4P-PDOT (10 mg/kg) pre-treatment blocks the effect of MLT on Tb during the light phase. (D) 4P-PDOT (10 mg/kg) injected during the light phase does not affect Tb. (E) Pre-treatment with luzindole (10 mg/kg) blocks the effect of MLT on Tb during the light phase. (F) luzindole (10 mg/kg) injected during the light phase does not affect Tb. Data are expressed as mean ± SEM (graded shades). Lights on at 7:30 a.m. and off at 7:30 p.m. * p < 0.05 vs. vehicle; two-way ANOVA for repeated measures followed by Bonferroni post hoc test. Inj: s.c. injection of either vehicle, MLT, MLT + 4P-PDOT, 4P-PDOT, MLT + luzindole, or luzindole.
Ijms 20 02452 g002
Ijms 20 02452 g003 550
Figure 3. Changes in Tb after UCM924 (40 mg/kg, s.c.) treatment during the light and the dark phase. (A) UCM924 (40 mg/kg) administered at 5:00 a.m. (light phase) decreases Tb prior the light–dark shift compared with vehicle. (B) UCM924 (40 mg/kg) administered at 5:00 p.m. does not produce any change in the Tb compared with vehicle. (C) 4P-PDOT pre-treatment blocks the effect of UCM924 on Tb during the dark phase. (D) 4P-PDOT (10 mg/kg) injected during the dark phase does not affect Tb. Data are expressed as mean ± SEM (graded shades). Lights on at 7:30 a.m. and off at 7:30 p.m. * p < 0.05 versus vehicle; two-way ANOVA for repeated measures followed by Bonferroni post hoc test. Inj: s.c. injection of either vehicle, UCM924, UCM924 + 4P-PDOT, or 4P-PDOT.
Figure 3. Changes in Tb after UCM924 (40 mg/kg, s.c.) treatment during the light and the dark phase. (A) UCM924 (40 mg/kg) administered at 5:00 a.m. (light phase) decreases Tb prior the light–dark shift compared with vehicle. (B) UCM924 (40 mg/kg) administered at 5:00 p.m. does not produce any change in the Tb compared with vehicle. (C) 4P-PDOT pre-treatment blocks the effect of UCM924 on Tb during the dark phase. (D) 4P-PDOT (10 mg/kg) injected during the dark phase does not affect Tb. Data are expressed as mean ± SEM (graded shades). Lights on at 7:30 a.m. and off at 7:30 p.m. * p < 0.05 versus vehicle; two-way ANOVA for repeated measures followed by Bonferroni post hoc test. Inj: s.c. injection of either vehicle, UCM924, UCM924 + 4P-PDOT, or 4P-PDOT.
Ijms 20 02452 g003
Ijms 20 02452 g004 550
Figure 4. Changes in Tb after UCM871 (14 mg/kg, s.c.) treatment during the light and the dark phase. (A) UCM871 administered at 5:00 a.m. (dark phase) does not produce any change in the Tb compared with vehicle. (B) UCM871 administered at 5:00 p.m. (light phase) increases Tb after the light–dark transition compared with vehicle. (C) Luzindole pre-treatment blocks the effect of UCM871 on Tb. Data are expressed as mean ± SEM (graded shades). Lights on at 7:30 a.m. and off at 7:30 p.m. * p < 0.05 versus vehicle; two-way ANOVA for repeated measures followed by Bonferroni post hoc test. Inj: s.c. injection of either vehicle, UCM871, or UCM871 + luzindole.
Figure 4. Changes in Tb after UCM871 (14 mg/kg, s.c.) treatment during the light and the dark phase. (A) UCM871 administered at 5:00 a.m. (dark phase) does not produce any change in the Tb compared with vehicle. (B) UCM871 administered at 5:00 p.m. (light phase) increases Tb after the light–dark transition compared with vehicle. (C) Luzindole pre-treatment blocks the effect of UCM871 on Tb. Data are expressed as mean ± SEM (graded shades). Lights on at 7:30 a.m. and off at 7:30 p.m. * p < 0.05 versus vehicle; two-way ANOVA for repeated measures followed by Bonferroni post hoc test. Inj: s.c. injection of either vehicle, UCM871, or UCM871 + luzindole.
Ijms 20 02452 g004
Ijms 20 02452 g005 550
Figure 5. (A) Changes in Tb after the administration of the MLT MT3 agonist GR135531 (10 mg/kg) during the dark phase. (B) Prazosin (10 mg/kg) pre-treatment does not block the effects of MLT on Tb during the light phase. (C) Prazosin (10 mg/kg) injected during the light phase does not affect Tb. Data are expressed as mean ± SEM (graded shades). Lights off at 7:30 p.m. * p < 0.05 versus vehicle; two-way ANOVA for repeated measures followed by Bonferroni post hoc test. Inj: s.c. injection of either vehicle, GR135531, MLT + prazosin, or prazosin.
Figure 5. (A) Changes in Tb after the administration of the MLT MT3 agonist GR135531 (10 mg/kg) during the dark phase. (B) Prazosin (10 mg/kg) pre-treatment does not block the effects of MLT on Tb during the light phase. (C) Prazosin (10 mg/kg) injected during the light phase does not affect Tb. Data are expressed as mean ± SEM (graded shades). Lights off at 7:30 p.m. * p < 0.05 versus vehicle; two-way ANOVA for repeated measures followed by Bonferroni post hoc test. Inj: s.c. injection of either vehicle, GR135531, MLT + prazosin, or prazosin.
Ijms 20 02452 g005
Ijms 20 02452 g006 550
Figure 6. Schematic representation of the experimental design. Body temperature (Tb) has been recorded every 15 min. For light–dark phase experiments, light was off at 7:30 p.m., whereas for dark–light phase experiments, light was on at 7:30 a.m. s.c.: subcutaneous.
Figure 6. Schematic representation of the experimental design. Body temperature (Tb) has been recorded every 15 min. For light–dark phase experiments, light was off at 7:30 p.m., whereas for dark–light phase experiments, light was on at 7:30 a.m. s.c.: subcutaneous.
Ijms 20 02452 g006

Share and Cite

MDPI and ACS Style

López-Canul, M.; Min, S.H.; Posa, L.; De Gregorio, D.; Bedini, A.; Spadoni, G.; Gobbi, G.; Comai, S. Melatonin MT1 and MT2 Receptors Exhibit Distinct Effects in the Modulation of Body Temperature across the Light/Dark Cycle. Int. J. Mol. Sci. 2019, 20, 2452. https://doi.org/10.3390/ijms20102452

AMA Style

López-Canul M, Min SH, Posa L, De Gregorio D, Bedini A, Spadoni G, Gobbi G, Comai S. Melatonin MT1 and MT2 Receptors Exhibit Distinct Effects in the Modulation of Body Temperature across the Light/Dark Cycle. International Journal of Molecular Sciences. 2019; 20(10):2452. https://doi.org/10.3390/ijms20102452

Chicago/Turabian Style

López-Canul, Martha, Seung Hyun Min, Luca Posa, Danilo De Gregorio, Annalida Bedini, Gilberto Spadoni, Gabriella Gobbi, and Stefano Comai. 2019. "Melatonin MT1 and MT2 Receptors Exhibit Distinct Effects in the Modulation of Body Temperature across the Light/Dark Cycle" International Journal of Molecular Sciences 20, no. 10: 2452. https://doi.org/10.3390/ijms20102452

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop